Stocktoria

Serina Therapeutics, Inc. SER

NYSE American · XASE · stock · Pharmaceutical Preparations · website · IPO 2018-11-29

Serina Therapeutics, Inc. statistics & valuation

Net margin-14755.4%
FCF margin-13856.9%

Market cap as of 2026-06-30. Multiples are price-derived and refreshed daily; everything else is from filings.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Gross margin3.2%61.8%86.8%92.8%85.9%73.9%88.0%
Operating margin-18478.5%-30442.9%-99.2%-20514.7%-5509.0%-2797.8%-726.8%-805.5%-474.6%
Net margin-14755.4%-19894.6%167.1%-30770.6%-6024.3%-3009.7%-703.4%-537.4%-468.7%
FCF margin-13856.9%-30641.1%-2223.8%-625.1%-574.2%-447.7%
Return on assets-276.0%-165.7%58.8%-322.8%-275.0%-276.8%-163.3%-70.3%-68.3%
Return on equity51843.2%-1738.1%-16.3%27.7%73.1%201.4%-464.4%-91.1%-79.1%
Debt / equity-0.48×-1.11×
Current ratio1.712.405.390.240.250.431.233.22

Source: SEC EDGAR filings · CIK 0001708599 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.